Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Team Grant: Mucosal Immunology for HIV Vaccine Development

University of Toronto

$180,000.00

Understanding mucosal protection against HIV: delineating interactions between the immune system, microbiome and mucus.

FY 2014-15

Summary
Most new HIV infections are acquired through sex, but sexual HIV transmission is surprisingly inefficient. This has affected the development of an effective HIV vaccine in several important ways. First, the rarity of transmission makes it very difficult to study genital immune events that result in transmission, which would inform vaccine development. Therefore, many vaccines are developed and tested without considering human genital immunology. Second, the inefficiency of natural transmission has led vaccine researchers to develop artificial models of HIV transmission in primates and small animals. These 'mucosal gaps' have served as a significant obstacle to the development of an effective HIV vaccine. Our previous work demonstrated that unique aspects of the human genital tract serve as critical determinants of HIV transmission risk, including normal genital bacteria, genital immunology and the presence of genital mucus. RESEARCH HYPOTHESES: 1) Normal genital bacteria shape HIV transmission risk. 2) Genital antibodies that can neutralize HIV are induced by the normal genital bacteria. 3) Genital mucus can both help to block HIV infection but also the ability of vaccines to induce local immunity: new "nanoparticle" vaccines preserve the mucus barrier while permitting the induction of HIV immune responses. SPECIFIC AIMS: 1) To define the impact of normal genital bacteria on genital mucus and HIV susceptibility. 2) To understand how local genital antibodies that block HIV can be induced by genital bacteria. 3) Development and preclinical testing of a mucosal HIV "nanovaccine" that can penetrate mucus. The proposed work applies our expertise in mucosal immunology, human bacterial ecology and vaccine development within unique international human cohorts and validated humanized mouse models. We believe that the results have the potential to change current paradigms of mucosal HIV transmission and host immune protection.
Program
Team Grant: Mucosal Immunology for HIV Vaccine Development
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
312320
Name
Kaul Rupert
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Bill & Melinda Gates Foundation
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Mucosal Immunology for HIV Vaccine Development
Projecttitle
Understanding mucosal protection against HIV: delineating interactions between the immune system, microbiome and mucus.
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$180,000
Cihrequipment2
$0
Programname2
Team Grant: Mucosal Immunology for HIV Vaccine Development
Keyworddelim
Hiv Explant Systems; Human Studies; Humanized Mice; Iga; Microbiome; Mucosal Immunology; T Cell Immunology
Abstract
Most new HIV infections are acquired through sex, but sexual HIV transmission is surprisingly inefficient. This has affected the development of an effective HIV vaccine in several important ways. First, the rarity of transmission makes it very difficult to study genital immune events that result in transmission, which would inform vaccine development. Therefore, many vaccines are developed and tested without considering human genital immunology. Second, the inefficiency of natural transmission has led vaccine researchers to develop artificial models of HIV transmission in primates and small animals. These 'mucosal gaps' have served as a significant obstacle to the development of an effective HIV vaccine. Our previous work demonstrated that unique aspects of the human genital tract serve as critical determinants of HIV transmission risk, including normal genital bacteria, genital immunology and the presence of genital mucus. RESEARCH HYPOTHESES: 1) Normal genital bacteria shape HIV transmission risk. 2) Genital antibodies that can neutralize HIV are induced by the normal genital bacteria. 3) Genital mucus can both help to block HIV infection but also the ability of vaccines to induce local immunity: new "nanoparticle" vaccines preserve the mucus barrier while permitting the induction of HIV immune responses. SPECIFIC AIMS: 1) To define the impact of normal genital bacteria on genital mucus and HIV susceptibility. 2) To understand how local genital antibodies that block HIV can be induced by genital bacteria. 3) Development and preclinical testing of a mucosal HIV "nanovaccine" that can penetrate mucus. The proposed work applies our expertise in mucosal immunology, human bacterial ecology and vaccine development within unique international human cohorts and validated humanized mouse models. We believe that the results have the potential to change current paradigms of mucosal HIV transmission and host immune protection.
Competitiondate
201406
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Kaul, Rupert
Approvedterm
3 ans 0 mois
Cihrcontribution2
HIV/AIDS~ $180,000~ $0~
University of Toronto - $180,000 Grant (2014-15) | Canada Spends